Quanterix Corp. (QTRX) - 10-Q Summary for Period Ended June 30, 2025
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the three and six months ended June 30, 2025. Quanterix Corporation is a life sciences company developing ultra-sensitive digital immunoassay platforms (Simoa technology) for research and diagnostics. The company operates as a single reporting unit. As of July 31, 2025, there were 46,465,915 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenues | $24,476 | $34,381 | $54,810 | $66,447 |
| Gross Profit | $11,300 | $22,234 | $27,716 | $40,782 |
| Gross Margin | 46.2% | 64.7% | 50.6% | 61.4% |
| Net Loss | $(30,013) | $(7,387) | $(50,517) | $(18,550) |
| Net Loss Per Share (Basic/Diluted) | $(0.77) | $(0.19) | $(1.30) | $(0.49) |
| Cash & Cash Equivalents | $132,896 | $47,002 | $132,896 | $47,002 |
| Marketable Securities | $128,276 | $232,413 | $128,276 | $232,413 |
| Total Liquidity (Cash + Securities) | $261,172 | $279,415 | $261,172 | $279,415 |
| Net Cash Used in Operating Activities (YTD) | $(19,543) | $(25,115) | $(19,543) | $(25,115) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 29% in Q2 2025 compared to Q2 2024. Product revenue fell 15% and Service revenue fell 48%. Management attributes this to reduced US federal research funding, decreased R&D spending by pharmaceutical customers, and the completion of a large collaboration agreement with Eli Lilly in late 2024.
- Goodwill Impairment: The company recorded a full goodwill impairment charge of $6.4 million in Q2 2025. This was triggered by a quantitative test following a decline in revenue and bookings due to macroeconomic conditions and new import tariffs.
- Restructuring Costs: The company incurred $1.3 million in restructuring costs in Q2 2025 related to a reduction in force announced in May 2025.
- Acquisition Activity:
- Emission, Inc. (Jan 2025): Acquired for a total consideration of $16.6 million (cash, holdback, and contingent consideration). This resulted in $6.6 million of contingent consideration liability and $12.9 million of intangible assets.
- Akoya Biosciences (July 2025): Completed post-period. Quanterix acquired Akoya for approximately 7.8 million shares of common stock and $19.6 million in cash. Additionally, Quanterix paid $82.1 million to settle Akoya's debt financing.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 30% in Q2 2025, driven by $6.2 million in non-recurring costs related to the Akoya acquisition and Emission earnout compensation.
Guidance, Outlook, and Risks
- Outlook: Management expects operating losses to continue through 2025. However, following the Akoya acquisition and cost-reduction initiatives (targeting $85 million in annualized savings), the combined company expects to reach cash flow breakeven in 2026.
- Product Launch: The new Simoa One instrument is expected to launch by the end of 2025 to help grow instrument sales.
- Internal Controls: The company disclosed that its internal control over financial reporting was not effective as of June 30, 2025, due to material weaknesses in inventory valuation and Accelerator Laboratory revenue accounting. Remediation efforts are ongoing.
- Risks: Key risks include continued softness in instrument sales due to constrained capital funding, the success of integrating Akoya, and the ability to achieve performance milestones for Emission earnout payments (up to $50 million).
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of remediation for material weaknesses in inventory valuation and revenue recognition, as these remain unremediated as of the filing date.
- Akoya Integration: Monitor the integration of Akoya Biosciences and the realization of the projected $85 million in annualized cost savings to validate the 2026 breakeven guidance.
- Revenue Trends: Track the recovery of instrument sales and the impact of the new Simoa One launch against the backdrop of reduced federal research funding.
- Liquidity Post-Akoya: Confirm the company's liquidity position after the $101.7 million cash outflow for the Akoya acquisition (purchase price + debt payoff) to ensure sufficient runway for operations.
- Emission Earnout: Assess the likelihood of achieving the technical and performance milestones required for the $60 million in potential future earnout payments to Emission shareholders.